{"id":7713,"date":"2022-06-25T07:07:19","date_gmt":"2022-06-25T07:07:19","guid":{"rendered":"https:\/\/ultimatehealthreport.com\/new-research-into-terpenes-could-change-medicine-forever\/"},"modified":"2022-06-25T07:07:19","modified_gmt":"2022-06-25T07:07:19","slug":"new-research-into-terpenes-could-change-medicine-forever","status":"publish","type":"post","link":"https:\/\/ultimatehealthreport.com\/new-research-into-terpenes-could-change-medicine-forever\/","title":{"rendered":"New Research Into Terpenes Could Change Medicine Forever"},"content":{"rendered":"


\n<\/p>\n

\t\t<\/p>\n

You\u2019ll often hear people say cannabis science is in its infancy. While it\u2019s true there is much more to learn about the plant, some regions of the world have been studying cannabis intensely for decades. <\/p>\n

The field of cannabis science was pioneered by Raphael Mechoulam in the 1960s. His research, based in Israel, laid the foundation for our modern understanding of the herb. <\/p>\n

Nearly 60 years later, Israel remains a leading force in the study of cannabis.\u00a0<\/p>\n

Nadav Eyal, CEO and co-founder of Eybna Technologies, is building on this body of research and pioneering his own studies on terpenes, cannabinoids, and their interactions with the endocannabinoid system. <\/p>\n

In 2020, Eybna discovered a cannabinoid formulation that effectively blocked the novel coronavirus from penetrating living cells. The combination, known as the NT-VRL formulation, is now undergoing clinical study as a potential treatment for the disease.\u00a0<\/p>\n

While NT-VRL is a remarkable discovery, it may ultimately pale in comparison to Eybna\u2019s more recent revelation around receptor-specific cannabinoid formulations. <\/p>\n

In this interview, Eyal discusses what inspired him to study cannabis and how his latest research will change the industry forever. This conversation has been edited for length and clarity. Hear the whole interview at www.cannatechtoday.com\/podcasts.<\/p>\n

\n